Injectable hydrogels for treating skin injuries in diabetic animal models: a systematic review

One of the main causes of chronic wounds is diabetes mellitus (DM), a metabolic disease characterized by chronic hyperglycemia. In this context, hydrogels have been used as a promising treatment for stimulating tissue ingrowth and healing in these injuries. This systematic review aimed to evaluate the findings of studies that investigated the effects of injectable hydrogels of various origins on skin wound healing using in vivo experimental models in diabetic rats.

This review was conducted in March 2023 using two databases, PubMed and Scopus, following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) guidelines and the SYRCLE (Systematic Review Centre for Laboratory Animal Experimentation). The following Medical Subject Headings (MeSH) descriptors were used: "hydrogels," "injectable," "in vivo," "diabetes mellitus," and "skin wound dressing."

After the eligibility assessment, 12 studies were selected and analyzed from an initial 95 articles identified across databases. The studies demonstrated that a variety of injectable hydrogels showed biocompatibility and bioactivity, effectively interacting with skin tissue in diabetic wound models. These hydrogels were assessed for their compositions, structural properties, and in vivo effects on wound closure, inflammation reduction, and collagen deposition. Also, immunofluorescence analyses revealed increased expression of neoangiogenesis markers and reduced inflammatory factors in treated groups, highlighting the hydrogels potential for enhancing skin healing in diabetic wounds.

Injectable hydrogels show significant potential as an effective treatment for diabetic skin wounds, though further clinical studies are needed to fully assess their biological performance.